Daniel O’Connell

Dr. O’Connell, a Partner at Novo Ventures, has a proven track record in venture capital investments and corporate development. He was previously Executive Director of Equity and Venture Capital at Bristol Myers Squibb, where he was responsible for managing and operationalizing the $4.5B equity portfolio, comprising both direct equity investments and LP positions in venture funds. While at BMS, he was also a transaction lead in the 2020 acquisition of MyoKardia for $13.1 billion. Dr. O’Connell started in venture investing at OrbiMed Advisors and Arix Bioscience, where he led and supported investments in oncology, orphan diseases, and novel science developing technologies to address unmet medical needs. Dr. O’Connell received his M.D. and Ph.D. at the Tufts University School of Medicine and holds a B.S. from MIT.